D316 is critical for the enzymatic activity and HIV-1 restriction potential of human and rhesus APOBEC3B

Virology

Volumn 441, Issue 1, 2013, Pages 31-39

  McDougle, Rebecca M ^a   Hultquist, Judd F ^a,b   Stabell, Alex C ^c   Sawyer, Sara L ^c   Harris, Reuben S ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

APOBEC3B; DNA cytosine deamination; Human immunodeficiency virus type 1 (HIV 1); Restriction factors; Rhesus macaque

Indexed keywords

AMINO ACID; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; ASPARTIC ACID; COMPLEMENTARY DNA; CYTOSINE; CYTOSINE DEAMINASE; DEAMINASE; THYMINE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CLONE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME SPECIFICITY; ESCHERICHIA COLI; GENE MUTATION; GENE PRODUCT; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RETROPOSON; RETROVIRUS; RHESUS MONKEY; VIRUS INHIBITION;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE; CYTIDINE DEAMINASE; DNA MUTATIONAL ANALYSIS; GENOTYPE; HIV-1; HUMANS; MACACA MULATTA; POINT MUTATION;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; PRIMATES;

EID: 84877614803     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.03.003     Document Type: Article

References (58)

1. Albin J.S., LaRue R.S., Weaver J.A., Brown W.L., Shindo K., Harjes E., Matsuo H., Harris R.S. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J. Biol. Chem. 2010, 285(52):40785-40792.
2. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 2004, 14(15):1392-1396.
3. Bogerd H.P., Doehle B.P., Wiegand H.L., Cullen B.R. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Nat. Acad. Sci. U.S.A. 2004, 101(11):3770-3774.
4. Bogerd H.P., Wiegand H.L., Doehle B.P., Lueders K.K., Cullen B.R. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res. 2006, 34(1):89-95.
5. Bogerd H.P., Wiegand H.L., Hulme A.E., Garcia-Perez J.L., O'Shea K.S., Moran J.V., Cullen B.R. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Nat. Acad. Sci. U.S.A. 2006, 103(23):8780-8785.
6. Bogerd H.P., Wiegand H.L., Doehle B.P., Cullen B.R. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 2007, 364(2):486-493.
7. Bulliard Y., Narvaiza I., Bertero A., Peddi S., Rohrig U.F., Ortiz M., Zoete V., Castro-Diaz N., Turelli P., Telenti A., Michielin O., Weitzman M.D., Trono D. Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. J. Virol. 2011, 85(4):1765-1776.
8. Burns M.B., Lackey L., Carpenter M.A., Rathore A., Land A.M., Leonard B., Refsland E.W., Kotandeniya D., Tretyakova N., Nikas J.B., Yee D., Temiz N.A., Donohue D.E., McDougle R.M., Brown W.L., Law E.K., Harris R.S. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013, February 6th, advance online publication. 10.1038/nature11881.
9. Carpenter M.A., Rajagurubandara E., Wijesinghe P., Bhagwat A.S. Determinants of sequence-specificity within human AID and APOBEC3G. DNA Repair (Amst) 2010, 9(5):579-587.
10. Carpenter M.A., Li M., Rathore A., Lackey L., Law E.K., Land A.M., Leonard B., Shandilya S.M., Bohn M.F., Schiffer C.A., Brown W.L., Harris R.S. Methyl- and normal-cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J. Biol. Chem. 2012, 287(41):34801-34808.
11. Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., Landau N.R., Weitzman M.D. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 2006, 16(5):480-485.
12. Conticello S.G., Thomas C.J., Petersen-Mahrt S.K., Neuberger M.S. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 2005, 22(2):367-377.
13. Dang Y., Abudu A., Son S., Harjes E., Spearman P., Matsuo H., Zheng Y.H. Identification of a single amino acid required for APOBEC3 antiretroviral cytidine deaminase activity. J. Virol. 2011, 85(11):5691-5695.
14. Doehle B.P., Schafer A., Cullen B.R. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 2005, 339(2):281-288.
15. Duggal N.K., Malik H.S., Emerman M. The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection. J Virol 2011, 85(21):11361-11371.
16. Esnault C., Priet S., Ribet D., Heidmann O., Heidmann T. Restriction by APOBEC3 proteins of endogenous retroviruses with an extracellular life cycle: ex vivo effects and in vivo "traces" on the murine IAPE and human HERV-K elements. Retrovirology 2008, 5:75.
17. Gervaix A., West D., Leoni L.M., Richman D.D., Wong-Staal F., Corbeil J. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc. Nat. Acad. Sci. U.S.A. 1997, 94(9):4653-4658.
18. Haché G., Liddament M.T., Harris R.S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 2005, 280(12):10920-10924.
19. Haché G., Shindo K., Albin J.S., Harris R.S. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr. Biol. 2008, 18(11):819-824.
20. Hakata Y., Landau N.R. Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. J Biol Chem 2006, 281(48):36624-36631.
21. Harris R.S., Hultquist J.F., Evans D.T. The restriction factors of human immunodeficiency virus. J. Biol. Chem. 2012.
22. Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L., Brown W.L., Harris R.S. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 2011, 85(21):11220-11234.
23. Jónsson S.R., Haché G., Stenglein M.D., Fahrenkrug S.C., Andrésdóttir V., Harris R.S. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res. 2006, 34(19):5683-5694.
24. Kidd J.M., Newman T.L., Tuzun E., Kaul R., Eichler E.E. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 2007, 3(4):e63.
25. Kinomoto M., Kanno T., Shimura M., Ishizaka Y., Kojima A., Kurata T., Sata T., Tokunaga K. All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res. 2007, 35(9):2955-2964.
26. Kohli R.M., Abrams S.R., Gajula K.S., Maul R.W., Gearhart P.J., Stivers J.T. A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J. Biol. Chem. 2009, 284(34):22898-22904.
27. LaRue R.S., Jónsson S.R., Silverstein K.A., Lajoie M., Bertrand D., El-Mabrouk N., Hötzel I., Andrésdóttir V., Smith T.P., Harris R.S. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol. Biol. 2008, 9:104.
28. LaRue R.S., Andrésdóttir V., Blanchard Y., Conticello S.G., Derse D., Emerman M., Greene W.C., Jónsson S.R., Landau N.R., Löchelt M., Malik H.S., Malim M.H., Münk C., O'Brien S.J., Pathak V.K., Strebel K., Wain-Hobson S., Yu X.F., Yuhki N., Harris R.S. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 2009, 83(2):494-497.
29. Lackey L., Demorest Z.L., Land A.M., Hultquist J.F., Brown W.L., Harris R.S. APOBEC3B and AID have similar nuclear import mechanisms. J. Mol. Biol. 2012, 419(5):301-314.
30. Li M., Shandilya S.M., Carpenter M.A., Rathore A., Brown W.L., Perkins A.L., Harki D.A., Solberg J., Hook D.J., Pandey K.K., Parniak M.A., Johnson J.R., Krogan N.J., Somasundaran M., Ali A., Schiffer C.A., Harris R.S. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem. Biol. 2011, 7(3):506-517.
31. Love R.P., Xu H., Chelico L. Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A. J. Biol. Chem. 2012, 287(36):30812-30822.
32. Malim M.H., Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microb. 2008, 3(6):388-398.
33. Mangeat B., Turelli P., Liao S., Trono D. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 2004, 279(15):14481-14483.
34. Miyagi E., Opi S., Takeuchi H., Khan M., Goila-Gaur R., Kao S., Strebel K. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 2007, 81(24):13346-13353.
35. Muckenfuss H., Hamdorf M., Held U., Perkovic M., Lower J., Cichutek K., Flory E., Schumann G.G., Münk C. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 2006, 281(31):22161-22172.
36. Münk C., Willemsen A., Bravo I.G. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol. Biol. 2012, 12:71.
37. Navarro F., Bollman B., Chen H., Konig R., Yu Q., Chiles K., Landau N.R. Complementary function of the two catalytic domains of APOBEC3G. Virology 2005, 333(2):374-386.
38. Olson M.E., Li M., Harris R.S., Harki D.A. Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold. Chem. Med. Chem. 2013, 8(1):112-117.
39. Rausch J.W., Chelico L., Goodman M.F., Le Grice S.F. Dissecting APOBEC3G substrate specificity by nucleoside analog interference. J. Biol. Chem. 2009, 284(11):7047-7058.
40. Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L., Harris R.S. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 2010, 38(13):4274-4284.
41. Refsland E.W., Hultquist J.F., Harris R.S. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 2012, 8(7):e1002800.
42. Rose K.M., Marin M., Kozak S.L., Kabat D. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res. Hum. Retroviruses 2005, 21(7):611-619.
43. Sawyer S.L., Emerman M., Malik H.S. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2004, 2(9):E275.
44. Schmitt K., Guo K., Algaier M., Ruiz A., Cheng F., Qiu J., Wissing S., Santiago M.L., Stephens E.B. Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution. Virology 2011, 419(1):24-42.
45. Schrofelbauer B., Chen D., Landau N.R. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Nat. Acad. Sci. U.S.A. 2004, 101(11):3927-3932.
46. Schumacher A.J., Haché G., MacDuff D.A., Brown W.L., Harris R.S. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 2008, 82(6):2652-2660.
47. Shandilya S.M., Nalam M.N., Nalivaika E.A., Gross P.J., Valesano J.C., Shindo K., Li M., Munson M., Royer W.E., Harjes E., Kono T., Matsuo H., Harris R.S., Somasundaran M., Schiffer C.A. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 2010, 18(1):28-38.
48. Stenglein M.D., Harris R.S. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 2006, 281(25):16837-16841.
49. Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 2010, 17(2):222-229.
50. Thielen B.K., McNevin J.P., McElrath M.J., Hunt B.V., Klein K.C., Lingappa J.R. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J. Biol. Chem. 2010, 285(36):27753-27766.
51. Virgen C.A., Hatziioannou T. Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins. J. Virol. 2007, 81(24):13932-13937.
52. Wang M., Rada C., Neuberger M.S. Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID. J. Exp. Med. 2010, 207(1):141-153.
53. Wijesinghe P., Bhagwat A.S. Efficient deamination of 5-methylcytosines in DNA by human APOBEC3A, but not by AID or APOBEC3G. Nucleic Acids Res. 2012, 40(18):9206-9217.
54. Wissing S., Montano M., Garcia-Perez J.L., Moran J.V., Greene W.C. Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J. Biol. Chem. 2011, 286(42):36427-36437.
55. Xu H., Svarovskaia E.S., Barr R., Zhang Y., Khan M.A., Strebel K., Pathak V.K. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Nat. Acad. Sci. U.S.A. 2004, 101(15):5652-5657.
56. Yu Q., Chen D., Konig R., Mariani R., Unutmaz D., Landau N.R. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 2004, 279(51):53379-53386.
57. Zhang J., Webb D.M. Rapid evolution of primate antiviral enzyme APOBEC3G. Hum. Mol. Genet. 2004, 13(16):1785-1791.
58. Zhen A., Wang T., Zhao K., Xiong Y., Yu X.F. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J. Virol. 2009, 84(4):1902-1911.